glaxosmithkline-and-sanofi-covid-19-vaccine-to-start-human-trials-1599138263768.jpg
Source: istoc

GlaxoSmithKline and Sanofi Start Human Trials for COVID-19 Vaccine

By

Updated

On Thursday, Sept. 3, GlaxoSmithKline and Sanofi announced that their potential coronavirus vaccine candidate has started human trials in the U.S. The companies expect the clinical trial results to be released in early December. In April, GlaxoSmithKline and Sanofi joined forces to develop an effective treatment for the devastating coronavirus pandemic.

What's the latest coronavirus vaccine news?

Currently, there are about 23 vaccines in clinical trials globally. Johnson & Johnson, AstraZeneca, and Pfizer are competing to develop vaccines to halt the COVID-19 pandemic. Earlier this week, the U.K. government ordered about 100 million doses of AstraZeneca’s COVID-19 vaccine. AstraZeneca’s vaccine is in advanced clinical trials.

Currently, the U.S. has more than 6.1 million coronavirus cases based on data compiled by Johns Hopkins University. At least 185,750 deaths in the U.S. have been linked to the coronavirus outbreak.

GlaxoSmithKline and Sanofi COVID-19 Vaccine to Start Human Trials
Source: Pixabay

What is the GlaxoSmithKline and Sanofi coronavirus vaccine?

GlaxoSmithKline and Sanofi announced that they started clinical trials for their coronavirus vaccine candidate. The two companies said that 440 adults would be given the COVID-19 vaccine across 11 sites in the U.S. The initial results from the clinical trials will likely be released in early December. If the results are satisfactory, the two companies would begin the Phase 3 trial before the end of 2020. The company plans to apply for regulatory approval of the COVID-19 vaccine in the first half of 2021.

According to a report from The Guardian, “The vaccine being developed by London-headquartered GSK and Paris-based Sanofi combines existing technology used by Sanofi to make its flu vaccine, along with an add-on from GSK, known as an adjuvant, which can be mixed with a vaccine to trigger a stronger immune reaction.”

What is GlaxoSmithKline's stock price today?

In pre-market trading on Sept. 3, GlaxoSmithKline stock was down about 0.4 percent at $39.76. The stock rose 2.4 percent on Sept. 2 and closed at $39.90 with a market capitalization of $99.3 billion. The stock has risen by 0.4 percent in the last five days and fallen by 5.2 percent in the last year. GlaxoSmithKline stock is trading 17.3 percent below its 52-week high of $48.25 and 26.9 percent above its 52-week low of $31.43. Year-to-date, the stock has fallen by 15.1 percent.

glaxosmithkline-stock-price-1599138472938.jpg
Source: istock

What is Sanofi's stock price today?

In pre-market trading today, Sanofi stock was up about 0.6 percent at $50.79. The stock rose 1.1 percent on Sept. 2 and closed at $50.47 with a market capitalization of $127.6 billion. Sanofi stock has fallen by 0.6 percent in the last five days and risen by 12.7 percent in the last year. The stock is trading 8.2 percent below its 52-week high of $55 and 34.2 percent above its 52-week low of $37.62. Year-to-date, the stock has risen by 0.5 percent.

More From Market Realist